Takeda China and China hereditary angioedema care center Swift held a popular science pop-up exhibition

On the occasion of the 10th "World Hereditary Angioedema Day", in order to further enhance the public's awareness of hereditary angioedema (HAE) and increase attention to the patient population, Takeda China has joined hands with China's hereditary angioedema care Center Swift, together to create "Say'No' to Asphyxia" World Hereditary Angioedema Day Science Pop-up Exhibition, with multimedia graphic and video exhibition combined with online and offline interactive experience, visual presentation of HAE disease knowledge and real patient journey, appealing to the society All walks of life give more care and support to patients
.

Professor Li Dingguo, Chairman of the Shanghai Rare Disease Prevention and Treatment Foundation, Professor Guo Yinshi, Director of the Department of Allergy, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Ms.

Hereditary angioedema (HAE) is a rare autosomal dominant genetic disease
.

Due to the lack of C1 esterase inhibitor (C1INH) in the body or the defective function, the patient has acute edema in various parts of the body such as limbs, face, genitals, respiratory tract and gastrointestinal mucosa without warning, which seriously affects daily work and study , Life and emotional health

Professor Li Dingguo, Chairman of the Shanghai Rare Disease Prevention and Control Foundation, pointed out: “Many rare diseases, including HAE, have common pain points such as low disease awareness, insufficient diagnosis rate, and tortuous path of patient consultation.
The public is concerned about these related rare diseases.
The understanding and cognition of people need to be improved urgently
.

I’m very happy to see that this popular science pop-up exhibition helps the audience to more intuitively understand the related knowledge of the rare disease of HAE through a more popular and intuitive art display form, which will help improve the public and the public.

Hereditary angioedema is unpredictable, and the clinical symptoms at the onset are more serious, even life-threatening
.

Among them, the most deadly is the mucosal edema of the upper respiratory tract, which can progress rapidly and cause the patient to have difficulty breathing or suffocation.

Professor Guo Yinshi, director of the Department of Allergy, Renji Hospital, Shanghai Jiaotong University School of Medicine, said: “Heditary angioedema is a rare disease with potentially fatal risks, which seriously affects the quality of life and physical and mental health of patients.
We need to pay more attention and regulate patients.
The
current authoritative diagnosis and treatment guidelines at home and abroad recommend long-term preventive treatment for HAE patients to reduce the impact of HAE on patients’ daily life and prevent fatal edema; when HAE is acute, effective treatment should be taken.

Treat as needed to reduce seizure-related complications and mortality

       Up to now, the survival and diagnosis and treatment status of HAE patients in China is still not optimistic.
Patients and families generally face challenges such as high misdiagnosis rate and high long-term treatment burden.
At the same time, patients are often exposed to anytime due to delayed diagnosis or limited efficacy of existing treatment options.
May occur upper respiratory tract mucosal edema and suffocation in danger of death
.

HAE previously lacked targeted therapeutic drugs in China.

       Ms.
Zhang Nan, head of Swift at the China Hereditary Angioedema Care Center, said: “Due to frequent occurrences of acute edema without warning, HAE patients cannot work and study normally, which seriously affects our quality of life; especially for laryngeal edema.
The worries onset make us live in anxiety and fear all the time
.

We hope that through this exhibition, the general public can'see','hear' and'feel' the true voice of HAE patients as a minority, and give it to the patient group With more understanding and support, join us in saying'no' to suffocation

       As one of the representative companies in the field of rare diseases, Takeda China, one of the organizers of this event, adheres to the spirit of "Patient First" and focuses on meeting the actual needs of China's rare disease patients including HAE patients
.

In the past year, Takeda China has accelerated the introduction of two targeted innovative drugs for long-term prevention and treatment of HAE and emergency response to China to help patients with HAE achieve the goal of "zero-onset" treatment